Explore our comprehensive coverage of cardiovascular disease, including scientific research, policy developments, environmental impacts, and solutions for a sustainable future.
The FDA's approval of the first in vivo base-editing therapy for cardiovascular risk marks a definitive shift from chronic care management to permanen...
Read Full Story →
Medical ResearchThe FDA’s approval of the first in vivo CRISPR therapy for familial hypercholesterolemia structura...
FashionA phase 3 randomized trial published in The Lancet on August 8, 2026, reveals that the oral drug ral...
